US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.
about
Cancer trials in sub-Saharan Africa: Aligning research and care.Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial.Evaluation of Cross-Calibrated 68Ge/68Ga Phantoms for Assessing PET/CT Measurement Bias in Oncology Imaging for Single- and Multicenter TrialsShould Response-Adapted Therapy Now Be the Standard of Care for Advanced Hodgkin's Lymphoma?Evolution of lymphoma staging and response evaluation: current limitations and future directions.Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations.Cancer clinical trials in persons with HIV infection.ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia.Sequential, Multiple Assignment, Randomized Trial Designs in Immuno-Oncology Research.Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation.The role of FDG-PET in Hodgkin lymphomaFrontline Therapy for Classical Hodgkin Lymphoma by Stage and Prognostic Factors.FDG-PET as a biomarker for early response in diffuse large B-cell lymphoma as well as in Hodgkin lymphoma? Ready for implementation in clinical practice?Modifying therapy in patients with advanced Hodgkin's lymphoma by integrating early metabolic response by interim PET-CT.Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma.18F-FDG PET/CT in Lymphoma: Has Imaging-Directed Personalized Medicine Become a Reality?Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma.PET-guided clinical trials in Hodgkin lymphoma: to agree or not to agree, that is the reviewer's question.Interim FDG-PET has no value in selecting patients who require treatment modification in both early- and advanced-stage Hodgkin lymphoma: response to Adams and Kwee.Hodgkin lymphoma: is there really a need for interim and end-of-treatment FDG-PET evaluations? - Response to Adams & Kwee.Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma.The predictive role of interim PET after the first chemotherapy cycle and sequential evaluation of response to ABVD in Hodgkin's lymphoma patients-the Polish Lymphoma Research Group (PLRG) Observational Study.Hodgkin Lymphoma: Differences in Treatment Between Europe and the United States/North America: Evolving Trends in Protocol Therapy.Serious concerns on the inability of FDG-PET in excluding residual viable lymphoma.The Strategies to Homogenize PET/CT Metrics: The Case of Onco-Haematological Clinical Trials.[18F]FDG-PET/CT in Hodgkin Lymphoma: Current Usefulness and Perspectives.How can we better predict treatment outcomes in classical Hodgkin's lymphoma?
P2860
Q33887891-89F44F76-8845-4533-A660-4CF13EA637B4Q37126978-6D04464E-4950-4FE5-AA04-943FD99DC5F4Q37458703-8E0663F0-38CA-4611-A67B-F845041EF6FCQ37558197-D0A04B35-B906-4740-A526-568C0C14BB5EQ37694536-0EE627C7-9269-4A70-9485-E9F0FE2C0501Q38671671-AE959611-DAF3-4C16-A2D4-03D391544DBFQ38775871-1358B3ED-6A66-478A-A2E6-91B23B696907Q38936874-B292DCA5-30E7-4554-BCFA-E6B4FE91AC95Q39324849-28E4C8E1-8F3A-4272-AC67-4F5D903ABD17Q40073118-DCE6A76A-0711-48B7-9249-829B4649DAE9Q40616101-A9451A6C-33B0-41F6-86F3-E71C407B8391Q41691698-2652F9DD-7232-4D56-8B94-2E1D845FAB5EQ42287385-1A5600C9-CFCE-4424-8383-F5AB4E9118B1Q42362028-0C394222-AC08-472F-99BC-CC0F69C7B177Q42370328-728CE290-BD62-4B99-8346-5633C01D30CBQ47563022-01ADDF45-8BE5-4918-AE39-102363CA8D48Q47808320-E7C246EA-994A-4279-93B7-45552BB14D13Q48127652-11C05CF6-4278-4AB0-BB24-369F53E862BEQ48194466-150C5EF1-AE97-47E4-BEC9-426A8399F355Q48194832-0F0A270E-60A0-439C-922A-C97D3F0D3780Q48330706-752B5E86-9EB7-43C1-8601-189852289B3CQ48364403-5D2D364F-930C-4AFA-88E2-144BCF7CABFEQ49821096-7FBFC79D-2060-4892-99F1-3BFC97CA7646Q50054777-336E3C2B-197C-452E-9A44-DD1350426640Q50058136-262F3A73-F815-4BB9-9C3B-14F0A2DFD4F3Q54152231-23D4E372-53C3-445C-9750-F25FA70FD7A9Q55220794-636A8162-8228-4A81-92E0-3A5F3BEC851DQ57301975-6630C319-8F93-4F10-A64D-4321602D4C0A
P2860
US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 April 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
US Intergroup Trial of Respons ...... outhwest Oncology Group S0816.
@en
US Intergroup Trial of Respons ...... outhwest Oncology Group S0816.
@nl
type
label
US Intergroup Trial of Respons ...... outhwest Oncology Group S0816.
@en
US Intergroup Trial of Respons ...... outhwest Oncology Group S0816.
@nl
prefLabel
US Intergroup Trial of Respons ...... outhwest Oncology Group S0816.
@en
US Intergroup Trial of Respons ...... outhwest Oncology Group S0816.
@nl
P2093
P2860
P50
P356
P1476
US Intergroup Trial of Respons ...... Southwest Oncology Group S0816
@en
P2093
Ann S LaCasce
Ariela Noy
Brad S Kahl
Bruce D Cheson
Craig H Moskowitz
David J Straus
Eric D Hsi
Erik S Mittra
Heiko Schöder
P2860
P304
P356
10.1200/JCO.2015.63.1119
P407
P577
2016-04-11T00:00:00Z